OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica 7/30/2024 Earnings Report $56.04 +7.04 (+14.37%) As of 04/24/2025 10:47 AM Eastern Earnings HistoryForecast Recordati Industria Chimica e Farmaceutica EPS ResultsActual EPS$0.70Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARecordati Industria Chimica e Farmaceutica Revenue ResultsActual Revenue$622.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARecordati Industria Chimica e Farmaceutica Announcement DetailsQuarterDate7/30/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsRecordati Industria Chimica e Farmaceutica's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Recordati Industria Chimica e Farmaceutica Earnings HeadlinesReviewing Hang Lung Group (OTCMKTS:HNLGY) and Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF)April 20, 2025 | americanbankingnews.comRecordati, la Fda amplia l’uso del farmaco Isturisa. Ma il titolo cade in borsa, ecco perchéApril 18, 2025 | msn.com[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.April 25, 2025 | Colonial Metals (Ad)3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%April 17, 2025 | finance.yahoo.comRecordati Industria Chimica e Farmaceutica S.p.A.April 7, 2025 | uk.investing.comRecordati upgraded to Hold from Sell at Deutsche BankMarch 19, 2025 | markets.businessinsider.comSee More Recordati Industria Chimica e Farmaceutica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Recordati Industria Chimica e Farmaceutica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recordati Industria Chimica e Farmaceutica and other key companies, straight to your email. Email Address About Recordati Industria Chimica e FarmaceuticaRecordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF), together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.View Recordati Industria Chimica e Farmaceutica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.